ABSTRACT
The Covid-19 pandemic has placed unprecedented strain on healthcare systems worldwide. Within this context, UK cancer services have undergone significant disruption to create capacity for the National Health Service. As a charity that endeavours to support bladder cancer (BC) patients and improve outcomes, Action Bladder Cancer UK (ABCUK) designed and administered a SurveyMonkey survey to investigate the prevalence of such disruption for BC patients. From 22nd April to 18th June 2020, 142 BC patients responded. Across all patient groups, 46.8% of patients described disruption to their treatment or follow-up. For non-muscle-invasive BC (NMIBC) patients, disruptions included postponement of: initial transurethral resection of bladder tumour (TURBT) (33.3%), subsequent TURBT (40.0%), and surveillance cystoscopy (58.1%). For NMIBC patients undergoing intravesical therapy, 68.4% experienced treatment postponements or curtailments. For muscle-invasive BC patients, 57.1% had experienced postponement of cystectomy and 14.3% had been changed from cystectomy to radiotherapy. Half of patients undergoing systemic chemotherapy also experienced disruption. Despite the survey’s limitations, we have demonstrated considerable disruption to the care of BC patients during the UK Covid-19 pandemic. To avoid a repeat, the UK BC community should define effective contingent ways of working ready for a possible ‘second wave’ of Covid-19, or any other such threat.
Competing Interest Statement
RT Bryan has contributed to advisory boards for Olympus Medical Systems & Janssen, and undertakes research funded by UroGen Pharma. Action Bladder Cancer UK (ABC UK) receives income from a variety of sources including public donations and grants, as well as educational grants from corporate supporters. In 2020 ABC UK has received educational grants from Bristol Myers Squibb, Janssen-Cilag Ltd and Merck Serono Limited.
Clinical Trial
This is a survey-based study administered by a bladder cancer charity via the charity's patient support groups.
Clinical Protocols
https://www.surveymonkey.co.uk/r/3Z6NMRV
Funding Statement
No external funding was received to undertake the work reported in the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK National Health Service (NHS) Health Research Authority considered the survey to be a service evaluation and so exempt from review by NHS Research Ethics Committees.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: RT Bryan has contributed to advisory boards for Olympus Medical Systems & Janssen, and undertakes research funded by UroGen Pharma.
Data Availability
Requests to access the data referred to in the manuscript can be made to Action Bladder Cancer UK or the corresponding author. Such requests will be reviewed by the charity Trustee Board in the context of the applicant's research objectives and pertinent regulatory permissions.
